Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: evinacumab

  • A New Treatment for Refractory Hyperlipidemia

    In patients with familial hypercholesterolemia who are not at target LDL cholesterol levels on maximum-tolerated doses of statins and PCSK9 inhibitors, evinacumab, which inhibits angiopoietin-like 3, reduces LDL by more than 50% at the highest doses with few side effects requiring drug discontinuation vs. placebo.